

BECKMANS GREENE STREET PHARMACY

2/18/2025

Date

Kristopher Rusinko, Pharm.D.
President
State Board of Pharmacy
4201 Patterson Avenue
Baltimore, Maryland 21215

RE: **Surrender of Permit**
Permit Number: P00939
Case Number: 24-002

Dear Mr. Rusinko and Members of the Board:

Please be advised that **BECKMANS GREENE STREET PHARMACY** ("Beckman's Pharmacy") has decided to voluntarily surrender its permit to operate as a pharmacy in the State of Maryland, Permit Number: **P00939** effective upon the earlier of: (i) 90 days from the date of this letter; or (ii) the sale of Beckman's Pharmacy. It is understood that upon surrender of its permit, Beckman's Pharmacy may not operate as a pharmacy in the State of Maryland as it is defined in the Maryland Pharmacy Act (the "Act"), Md. Code Ann., Health Occ. ("Health Occ.") §§ 12-101 *et seq.*, (2021 Repl. Vol. & 2024 Supp.) and other applicable laws.

Beckman's Pharmacy understands that this **Letter of Surrender** is a **PUBLIC DOCUMENT**, and, on the Board's, acceptance becomes a **FINAL ORDER** of the Board.

Beckman's Pharmacy's decision to voluntarily surrender its permit to operate as a pharmacy in the State of Maryland has been prompted by investigations conducted by the Maryland State Board of Pharmacy (the "Board"). The results of the investigations led the Board to issue disciplinary charges against Beckman's Pharmacy on or about July 17, 2024, under Case Number: 24-002 (See Attachment A – Charging Document dated July 17, 2024).

Beckman's Pharmacy has decided to voluntarily surrender its permit to operate as a pharmacy in the State of Maryland. Beckman's Pharmacy acknowledges that the Board could have revoked Beckman's Pharmacy's permit following an evidentiary hearing.

Beckman's Pharmacy acknowledges that the Board initiated an investigation of this matter and issued disciplinary charges against Beckman's Pharmacy. After its

investigation, the Board charged Beckman's Pharmacy with violating the following provisions of the Act:

Beckman's Pharmacy wishes to make clear that it has voluntarily, knowingly, and freely chosen to submit this Letter of Surrender to avoid the uncertainties which could arise from the prosecution of the charges and violation of probation determination under the Act. Beckman's Pharmacy acknowledges that for all purposes relevant to operating a pharmacy, those investigative findings will be treated as if proven by the preponderance of the evidence.

Beckman's Pharmacy acknowledges that the State would provide the following evidence if this matter had proceeded to a full evidentiary hearing:

On July 1, 2023, an inspector from the Maryland Office of Controlled Substances Administration ("OCSA") conducted an inspection of Beckman's Pharmacy. Most notably, the inspector observed that Beckman's Pharmacy had been delivering prescriptions to West Virginia without a pharmacy permit for West Virginia. The inspector directed Beckman's Pharmacy to cease deliveries to West Virginia.

On July 5, 2023, Beckman's Pharmacy and its co-owner/manager (the "Pharmacist") entered into a consent decree with the United States of America concerning their dispensing practices. To summarize, the consent order required Beckman's Pharmacy and the Pharmacist to implement practices to better identify red flag prescriptions and prohibited filling red flag prescriptions.

Following the consent order, the Board began an investigation and obtained Beckman's Pharmacy's PDMP report and Audit Log. OCSA's Clinical Pharmacist Inspector reviewed the PDMP report and Audit Log and drafted an opinion. The expert opinion contained the following prescribing details:

1. The PDMP report detailed 14,375 CDS prescriptions Beckman's Pharmacy dispensed from June 1, 2022, through December 1, 2023 (548 total days). Of the total number of CDS prescriptions:
 - a. 3,675 (~25%) were for Schedule II opioids;
 - b. 3,376 prescriptions (~23%) were for buprenorphine products used to treat substance abuse,
 - c. 3,267 prescriptions (~23%) were for schedule II stimulants; and
 - d. 2,077 prescriptions (~14%) were for benzodiazepines.
2. Of the 3,675 prescriptions for Schedule II opioids, 2,092 prescriptions were for immediate release oxycodone, which were broken down according to strengths:

- a. 455 prescriptions of oxycodone 5mg tablets;
 - b. 122 prescriptions of oxycodone/acetaminophen 7.5/325 tablets;
 - c. 1,228 prescriptions of oxycodone/acetaminophen 10/325 tablets;
 - d. 195 prescriptions of oxycodone 15mg tablets;
 - e. 60 prescriptions of oxycodone 20mg tablets; and
 - f. 27 prescriptions of oxycodone 30mg tablets.
3. "The great majority of the immediate-release oxycodone prescriptions dispensed by [Beckman's Pharmacy] had daily doses in the range of 20-60 MME."
 4. "The prescriptions for oxycodone 15mg, 20mg, and 30mg tablets in the dispensing report (282 total prescriptions or 13% of the immediate-release oxycodone prescriptions) had daily doses in the range of 68-150MME, with most being 90MME. Most of these high dose oxycodone prescriptions were prescribed by providers at [a health care practice], which is 91 miles away from the pharmacy."
 5. "[M]any patients received combinations of CDS drugs that are popularly abused when taken together, or have an increased risk of overdose when taken together. The combination seen most frequently was buprenorphine products combined with a benzodiazepine, such as clonazepam or alprazolam, and/or a schedule II stimulant, such as amphetamine or methylphenidate. Forty-seven patients were identified that had one of these combinations."

The Clinical Pharmacist Inspector ultimately found the following red flags:

1. "[P]atients receiving combinations of CDS medications that are frequently abused together or have an increased risk of overdose when combined."
2. "[S]ome patients receiving prescriptions for high doses of immediate-release oxycodone."
3. For most of the prescriptions for high doses of immediate-release oxycodone, the prescriber's practice was located 91 miles from Beckman's Pharmacy.

Beckman's Pharmacy understands that by executing this Letter of Surrender it is waiving any right to contest the charges in a formal evidentiary hearing at which Beckman's Pharmacy would have had the right to counsel, to confront witnesses, to give testimony, to call witnesses on my own behalf and all other substantive and procedural protections provided by law, including the right to appeal.

Beckman's Pharmacy understands that the Board will advise the National Practitioners' Data Bank of this Letter of Surrender, and in any response to any inquiry, that Beckman's Pharmacy has surrendered its permit, in lieu of a hearing on the revocation of its permit license, as further disciplinary action under the Act.

Beckman's Pharmacy also understands that in the event it would apply for a permit in any form in any other state or jurisdiction, that this Letter of Surrender and the underlying investigative documents may be released or published by the Board to the same extent as a final order that would result from disciplinary action, pursuant to Md. Code Ann., State Govt., § 10-611 *et seq.*, (2021 Repl. Vol & 2024 Supp.), and that this Letter of Surrender is considered a disciplinary action by the Board.

Beckman's Pharmacy affirms that on or before the date of Board's acceptance of this Letter of Surrender, it will provide to Board staff all permits issued by the Board.

Beckman's Pharmacy acknowledges that it may not rescind this Letter of Surrender in part or in its entirety for any reason whatsoever. Finally, Beckman's Pharmacy wishes to make clear that it has been advised of its right to be represented by the attorney of its choice throughout proceedings before the Board, including the right to counsel with an attorney prior to signing this Letter of Surrender. Beckman's Pharmacy understands both the nature of the Board's actions and this Letter of Surrender fully. Beckman's Pharmacy acknowledges that it understands and comprehends the language, meaning and terms and effect of this Letter of Surrender.

Beckman's Pharmacy voluntarily chooses to surrender its Maryland permit to operate a pharmacy pursuant to the terms and conditions set out herein. Beckman's Pharmacy makes this decision knowingly and voluntarily.

Date

02/18/2025



John A. Beckman

Owner

Beckman's Greene Street Pharmacy

Date

02-18-25



Kathleen A. Beckman

Owner

Beckman's Greene Street Pharmacy


NOTARY

STATE OF Maryland

CITY/COUNTY OF Allegany

I hereby certify that on this 18th day of February, 2025,
before me, a Notary Public of the State of Maryland and City/County aforesaid, personally
appeared JOHN A. BECKMAN and made an oath in due form that the foregoing Consent
Order was his voluntary act and deed.

AS WITNESS, my hand and Notary Seal.



Christina R. Byerley
Notary Public

My commission Expires: January 15, 2027


NOTARY

STATE OF Maryland

CITY/COUNTY OF Allegany

I hereby certify that on this 18th day of February, 2025,
before me, a Notary Public of the State of Maryland and City/County aforesaid, personally
appeared KATHLEEN A. BECKMAN and made an oath in due form that the foregoing
Consent Order was her voluntary act and deed.

AS WITNESS, my hand and Notary Seal.




Christina R. Byerley
Notary Public

My commission Expires: January 15, 2027

ACCEPTANCE

On behalf of the Maryland Board of Pharmacy, on this 31st day of May, 2025, I accept Beckmans Greene Street Pharmacy PUBLIC SURRENDER the permit in the State of Maryland.

 6/1/25

Kristopher Rusinko, Pharm. D.
President, Maryland Board of Pharmacy